Intellipharmaceutics International Inc. (IPCIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Intellipharmaceutics International Inc. (IPCIF) trades at $0.15 with AI Score 54/100 (Grade B). Intellipharmaceutics International Inc. Market cap: $4.96M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for IPCIF: IPCIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IPCIF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
IPCIF: the 6 perspectives are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Intellipharmaceutics International Inc. (IPCIF) Healthcare & Pipeline Overview
Intellipharmaceutics International Inc. specializes in researching, developing, and manufacturing novel and generic controlled-release and targeted-release oral solid dosage drugs in the U.S. Leveraging its patented Hypermatrix technology, the company addresses diverse therapeutic areas including neurology, cardiovascular, diabetes, and pain management, aiming to enhance drug delivery and patient outcomes.
What Is the Investment Thesis for IPCIF?
Intellipharmaceutics International Inc.'s investment thesis centers on its proprietary Hypermatrix technology, which enables the development of advanced controlled-release and targeted-release oral solid dosage drugs. This technology provides a competitive advantage in a market demanding improved drug delivery systems, potentially leading to enhanced patient outcomes and reduced dosing frequency. The company's existing portfolio of generic extended-release products across diverse therapeutic areas, such as neurology, cardiovascular, and pain management, represents a foundation for current revenue streams. Furthermore, the ongoing development of pipeline candidates like OxyContin and Regabatin XR, alongside its license and commercialization agreement with Par Pharmaceutical Inc., offers future growth catalysts. However, the company's current financial profile, marked by a negative profit margin of -4400.6% and a market capitalization of $4.96M, indicates significant financial challenges and a pre-commercial or early-stage commercialization phase, requiring careful evaluation of its ability to fund future R&D and commercialization efforts.
Based on FMP financials and quantitative analysis
IPCIF Key Highlights
- Market Capitalization: $0.00B, reflecting a micro-cap valuation and limited market presence.
- Profit Margin: -4400.6%, indicating substantial net losses relative to revenue, typical for R&D-intensive biotechnology firms.
- Gross Margin: 100.0%, suggesting that the cost of goods sold is negligible or that revenue is primarily derived from licensing or early-stage product sales without significant manufacturing costs.
- Beta: 0.40, indicating lower volatility compared to the broader market, which may be influenced by its micro-cap and OTC trading status.
- Employees: 11, highlighting a lean operational structure for a pharmaceutical research and development company.
Who Are IPCIF's Competitors?
IPCIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BRRGF BerGenBio ASA | $97.09 | +0.00% | $9.49B | 74 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| MIRM Mirum Pharmaceuticals, Inc. | $125.59 | +4.26% | $6.30B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| AXSM Axsome Therapeutics, Inc. | $240.85 | -1.42% | $12.39B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IPCIF's Key Strengths?
- Patented Hypermatrix technology offering advanced controlled-release drug delivery.
- Diverse portfolio of existing generic extended-release products in various therapeutic areas.
- Established license and commercialization agreement with Par Pharmaceutical Inc.
- Lean operational structure with a small, focused team of 11 employees.
- Pipeline of development products targeting significant medical needs, such as pain management.
What Are IPCIF's Weaknesses?
- Significant negative profit margin (-4400.6%) indicating substantial financial losses.
- Extremely small market capitalization ($0.00B), suggesting limited access to capital markets.
- Reliance on a single proprietary technology (Hypermatrix) for differentiation.
- Small employee base may limit the scale and speed of R&D and commercialization efforts.
- OTC trading status presents challenges related to liquidity and investor visibility.
What Could Drive IPCIF Stock Higher?
- Advancement of pipeline candidates, such as OxyContin and Regabatin XR, through preclinical and clinical development stages, potentially leading to future regulatory submissions.
- Continued commercialization efforts for existing generic extended-release products, aiming to maintain or expand market share through the license agreement with Par Pharmaceutical Inc.
- Potential for new strategic partnerships or licensing agreements that could provide additional funding or expand market access for its Hypermatrix technology or product candidates.
- Public disclosure of any new regulatory milestones or approvals for its drug formulations in the United States market.
What Are the Key Risks for IPCIF?
- Significant negative profit margin (-4400.6%) and a $4.96M market capitalization indicate substantial financial instability and potential challenges in securing future funding.
- High risk of R&D failure or delays in the development and regulatory approval of pipeline products, such as OxyContin and Regabatin XR, which are critical for future growth.
- Intense competition within the biotechnology and generic pharmaceutical industries, particularly from larger, more established companies with greater resources.
- Operational challenges and limited capacity due to a very small employee base (11 employees) for a company engaged in R&D and manufacturing.
- Risks associated with trading on the OTC Other tier, including extremely low liquidity, wide bid-ask spreads, price volatility, and limited public disclosure, making investment highly speculative.
What Are the Growth Opportunities for IPCIF?
- Advancement and Broader Application of Proprietary Hypermatrix Technology: The patented Hypermatrix technology represents a core competitive advantage for Intellipharmaceutics. Expanding the application of this technology to develop new controlled-release formulations for existing drugs or novel chemical entities could unlock significant market opportunities. This involves ongoing research and development to enhance the technology's capabilities, potentially leading to superior drug profiles that offer improved patient adherence and reduced side effects. The market for advanced drug delivery systems is continuously growing, driven by the need for more effective and patient-friendly treatments across various chronic conditions, offering a long-term growth trajectory.
- Commercialization of Advanced Pipeline Candidates: The successful development and commercialization of pipeline products, such as OxyContin (oxycodone hydrochloride controlled-release capsule) for pain and Regabatin XR (pregabalin extended-release capsule) for neuropathic pain, represent significant growth drivers. These products target substantial therapeutic markets with ongoing demand for effective pain management solutions. Advancing these candidates through clinical trials and securing regulatory approvals would enable Intellipharmaceutics to tap into new revenue streams, potentially transforming its financial profile. The timeline for such commercialization is dependent on regulatory processes and market acceptance, typically spanning several years.
- Leveraging and Expanding the Existing Generic Extended-Release Portfolio: Intellipharmaceutics currently offers a range of generic extended-release products, including Focalin XR, Keppra XR, and Effexor XR. Continued market penetration and sales growth of these established products can provide stable revenue. The generic drug market benefits from the expiration of branded drug patents, creating opportunities for cost-effective alternatives. By optimizing manufacturing processes, distribution channels, and potentially expanding the portfolio with additional generic extended-release formulations as patents expire, the company can capitalize on the consistent demand for affordable, high-quality pharmaceuticals.
- Strategic Licensing and Collaboration Agreements: The existing license and commercialization agreement with Par Pharmaceutical Inc. demonstrates the potential for Intellipharmaceutics to monetize its technology and product pipeline through partnerships. Seeking additional strategic alliances with larger pharmaceutical companies can provide access to greater financial resources, broader distribution networks, and specialized marketing expertise. Such collaborations can accelerate the development and commercialization of new products, reduce R&D risks, and expand market reach beyond current capabilities, particularly for novel formulations developed using the Hypermatrix technology. These agreements can generate upfront payments, milestone payments, and royalties.
- Addressing Unmet Medical Needs in Targeted Therapeutic Areas: By focusing its R&D efforts on specific therapeutic areas such as neurology, cardiovascular, diabetes, and pain, Intellipharmaceutics can develop highly specialized controlled-release solutions for conditions with significant unmet medical needs. This targeted approach allows the company to concentrate its resources on areas where its Hypermatrix technology can offer distinct advantages over existing treatments. Identifying and developing innovative formulations for diseases that currently lack optimal extended-release options could lead to strong market adoption and premium pricing, fostering long-term growth and establishing a stronger market position within these specialized segments.
What Opportunities Does IPCIF Have?
- Successful commercialization and regulatory approval of pipeline candidates like OxyContin and Regabatin XR.
- Expansion of Hypermatrix technology applications to new therapeutic areas or drug compounds.
- Formation of additional strategic partnerships and licensing agreements to broaden market reach and funding.
- Capitalizing on the growing demand for generic extended-release drugs as branded patents expire.
- Addressing unmet medical needs in specialized therapeutic segments with innovative drug delivery solutions.
What Threats Does IPCIF Face?
- Intense competition from larger, well-funded pharmaceutical and biotechnology companies.
- High costs and risks associated with pharmaceutical research, development, and regulatory approval processes.
- Potential for R&D failures or delays in pipeline product development.
- Challenges in securing adequate funding for ongoing operations and pipeline advancement given current financial metrics.
- Market acceptance and commercial success of new products are not guaranteed.
What Are IPCIF's Competitive Advantages?
- Proprietary Hypermatrix Technology: A patented drug delivery platform for controlled-release and targeted-release formulations, offering a unique competitive advantage.
- Specialized R&D Expertise: Focus on complex extended-release formulations requires specialized scientific and technical knowledge, creating barriers to entry.
- Established Product Portfolio: Existing generic extended-release drugs with regulatory approvals provide a market presence and revenue base.
- Strategic Licensing Agreement: The partnership with Par Pharmaceutical Inc. provides a commercialization pathway and validates the company's product development capabilities.
- Regulatory Approvals: Successfully navigating the stringent FDA approval process for multiple products demonstrates regulatory competence.
What Does IPCIF Do?
Intellipharmaceutics International Inc., founded in 1998 and headquartered in Toronto, Canada, operates as a pharmaceutical company dedicated to the research, development, and manufacturing of both novel and generic controlled-release and targeted-release oral solid dosage drugs within the United States market. The company's core technological differentiator is its patented Hypermatrix technology, which forms the foundation for its various drug delivery systems and product candidates. This technology is applied across a broad spectrum of therapeutic areas, including neurology, cardiovascular health, gastrointestinal tract disorders, diabetes, and pain management, aiming to improve drug efficacy and patient compliance through extended-release formulations. Intellipharmaceutics has developed and commercialized a portfolio of extended-release products. These include Focalin XR (dexmethylphenidate hydrochloride) for hyperactivity disorder, Keppra XR (levetiracetam) for partial onset seizures, Effexor XR (venlafaxine hydrochloride) for depression, and Protonix (pantoprazole sodium) for gastroesophageal reflux disease. The company's offerings also extend to Glucophage XR (metformin hydrochloride) for type 2 diabetes, Seroquel XR (quetiapine fumarate) for schizophrenia and bipolar disorder, Lamictal XR (lamotrigine) for epilepsy, Pristiq (desvenlafaxine) for depression, Coreg CR (carvedilol phosphate) for heart failure and hypertension, and Ranexa (ranolazine) for chronic angina. In addition to its marketed products, Intellipharmaceutics maintains a development pipeline, which includes candidates like OxyContin (oxycodone hydrochloride) controlled-release capsules for pain and Regabatin XR (pregabalin) extended-release capsules for neuropathic pain. The company has also established a license and commercialization agreement with Par Pharmaceutical Inc., facilitating the market reach of its products.
What Products and Services Does IPCIF Offer?
- Researches and develops novel and generic controlled-release and targeted-release oral solid dosage drugs.
- Manufactures pharmaceutical products primarily for the United States market.
- Utilizes its patented Hypermatrix technology for drug delivery systems.
- Develops product candidates across therapeutic areas like neurology, cardiovascular, diabetes, and pain.
- Offers marketed extended-release products such as Focalin XR, Keppra XR, and Effexor XR.
- Maintains a pipeline of development products, including OxyContin and Regabatin XR.
- Engages in licensing and commercialization agreements, such as with Par Pharmaceutical Inc.
- Focuses on improving drug efficacy and patient compliance through advanced drug delivery.
How Does IPCIF Make Money?
- Generates revenue from the sales of its portfolio of generic controlled-release and extended-release oral solid dosage drugs.
- Aims to derive future revenue from the successful development and commercialization of its pipeline product candidates.
- Secures income through licensing and commercialization agreements, such as the one with Par Pharmaceutical Inc., which may include upfront payments, milestone payments, and royalties.
- Invests heavily in research and development to create new drug formulations and expand its patented Hypermatrix technology applications.
What Industry Does IPCIF Operate In?
Intellipharmaceutics International Inc. operates within the highly competitive and innovation-driven biotechnology industry, a sub-sector of healthcare. The broader pharmaceutical market is characterized by a continuous demand for novel drug delivery systems that improve patient compliance, reduce side effects, and enhance therapeutic efficacy. The company's focus on controlled-release and targeted-release oral solid dosage drugs positions it within a specialized segment of the drug delivery market, which is driven by patent expirations of branded drugs and the need for lifecycle management strategies. While the market for generic extended-release drugs is substantial, it is also subject to intense competition from larger, more established pharmaceutical companies. Intellipharmaceutics' patented Hypermatrix technology aims to differentiate its offerings, allowing it to carve out a niche in therapeutic areas such as neurology, cardiovascular, and pain management. The industry is also heavily regulated, requiring extensive clinical trials and regulatory approvals, which can be time-consuming and costly.
Who Are IPCIF's Key Customers?
- Pharmaceutical distributors and wholesalers who purchase products for onward supply.
- Pharmacies and healthcare providers that dispense the company's drugs to patients.
- Ultimately, patients suffering from conditions in therapeutic areas like neurology, cardiovascular, diabetes, and pain who benefit from controlled-release medications.
- Strategic partners like Par Pharmaceutical Inc. for commercialization and distribution.
How Intellipharmaceutics International Inc. Is Valued
Intellipharmaceutics International Inc. carries a market capitalization of $4.96M, placing it in the micro-cap category. Relative to its peer group, IPCIF's quantitative score of 54/100 is below the peer average of 77/100.
Company Profile
Intellipharmaceutics International Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Isa Odidi MBA,. IPCIF has traded publicly since 2009.
ROE 27%Key Financial Metrics
Return on equity for Intellipharmaceutics International Inc. stands at 27.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -28.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -58.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Intellipharmaceutics International Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
IPCIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see potential upside, aligning their interests with shareholders.
- Positive community sentiment indicates growing belief in the company's pipeline and future prospects.
- Bullish community views highlight the potential of their drug delivery technology and its competitive advantages.
- Market perception is shifting as investors recognize the value of their intellectual property and potential partnerships.
Bear Case
- Limited news flow in the last 30 days raises concerns about near-term catalysts and visibility.
- Bearish community views point to concerns about regulatory hurdles and potential delays in drug approvals.
- Market perception reflects skepticism about the company's ability to secure funding for ongoing research and development.
- Recent insider selling, if any, could signal a lack of confidence in the company's short-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IPCIF Latest News
-
Stocks That Hit 52-Week Highs On Thursday
· Dec 12, 2019
IPCIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IPCIF.
Price Targets
Wall Street price target analysis for IPCIF.
IPCIF MoonshotScore
What does this score mean?
The MoonshotScore rates IPCIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Isa Odidi MBA,
Chief Executive Officer
Isa Odidi holds an MBA and is a seasoned leader in the pharmaceutical industry, guiding Intellipharmaceutics International Inc.'s strategic direction and operational execution. His expertise encompasses the complex landscape of pharmaceutical research, development, and manufacturing. As the head of a lean organization with 11 employees, Mr. Odidi is responsible for overseeing the company's efforts in advancing its patented Hypermatrix technology and managing its portfolio of controlled-release drug products and pipeline candidates.
Track Record: Under Mr. Odidi's leadership, Intellipharmaceutics International Inc. has focused on developing its proprietary Hypermatrix technology, leading to a portfolio of marketed generic extended-release drugs and a pipeline of novel candidates. Key achievements include the establishment of a diverse product offering across multiple therapeutic areas and the formation of a crucial license and commercialization agreement with Par Pharmaceutical Inc., which is vital for product distribution and market access.
IPCIF OTC Market Information
Intellipharmaceutics International Inc. trades on the OTC Other tier of the OTC market. This tier represents companies that do not meet the disclosure or financial standards of higher tiers like OTCQB, OTCQX, or even Pink Open Market. Companies in the 'OTC Other' category typically provide limited public information, making it challenging for investors to conduct comprehensive due diligence. This contrasts sharply with companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict reporting requirements, including regular audited financial statements and compliance with corporate governance standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Disclosure: The 'Unknown' disclosure status means investors have very little reliable public financial or operational information, increasing investment risk.
- Low Liquidity: Trading on the OTC Other tier typically results in extremely low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- Price Volatility: Low liquidity can lead to significant and unpredictable price fluctuations, as even small trades can disproportionately impact the stock price.
- Lack of Transparency: Reduced regulatory oversight compared to major exchanges can expose investors to higher risks of fraud or manipulation.
- Difficulty in Valuation: Without consistent and audited financial reporting, accurately valuing the company's shares becomes highly speculative.
- Attempt to locate any available financial statements or company updates, even if not formally audited or regularly filed.
- Thoroughly research the company's patented Hypermatrix technology and its competitive landscape.
- Investigate the terms and status of the license and commercialization agreement with Par Pharmaceutical Inc.
- Assess the current status and potential market for its pipeline products, such as OxyContin and Regabatin XR.
- Evaluate the background and track record of CEO Isa Odidi and other key management personnel.
- Understand the specific risks associated with the biotechnology industry and controlled-release drug development.
- Consider the implications of the company's small employee base on its operational capacity.
- Company founded in 1998, indicating a long operational history, albeit on OTC markets.
- Possession of patented Hypermatrix technology, suggesting proprietary intellectual property.
- Development and commercialization of a specific portfolio of generic extended-release drugs.
- Existence of a formal license and commercialization agreement with Par Pharmaceutical Inc.
- Clear identification of its headquarters in Toronto, Canada, and its operational focus in the United States.
What Investors Ask About Intellipharmaceutics International Inc. (IPCIF) — Healthcare
How does Intellipharmaceutics International Inc.'s Hypermatrix technology differentiate its products?
Intellipharmaceutics International Inc.'s core differentiation stems from its patented Hypermatrix technology, which is designed for developing novel and generic controlled-release and targeted-release oral solid dosage drugs. This technology allows for the precise control of drug release over an extended period, which can lead to several advantages. These include improved patient compliance by reducing the frequency of dosing, enhanced therapeutic efficacy by maintaining stable drug levels, and potentially reduced side effects. The technology is applied across various therapeutic areas, such as neurology, cardiovascular, and pain management, enabling the company to create specialized formulations that address specific medical needs and offer distinct benefits over immediate-release alternatives.
What are the financial implications of Intellipharmaceutics International Inc.'s current profitability and market capitalization?
Intellipharmaceutics International Inc. currently exhibits a profit margin of -4400.6% and a market capitalization of $4.96M. The significantly negative profit margin indicates that the company is incurring substantial losses relative to any revenue generated, which is common for biotechnology firms in intensive research and development phases or early commercialization stages. This suggests that current operations are not yet profitable and likely require external funding. The $4.96M market capitalization signifies an extremely small valuation, often associated with micro-cap or distressed companies, reflecting limited investor confidence or a very early stage of market recognition. While the gross margin is 100.0%, this likely implies revenue from licensing or early product sales without significant associated cost of goods sold, rather than robust profitability from scaled manufacturing.
What are the key risks associated with investing in Intellipharmaceutics International Inc., particularly given its OTC trading status?
Investing in Intellipharmaceutics International Inc. carries several significant risks, compounded by its OTC Other trading status. From a business perspective, the company faces substantial R&D risks, including potential failures or delays in the development and regulatory approval of its pipeline products like OxyContin and Regabatin XR. Its current financial state, marked by a -4400.6% profit margin and a $4.96M market capitalization, indicates severe financial instability and potential challenges in securing necessary funding for ongoing operations. Furthermore, the OTC Other tier status means there is 'Unknown' disclosure of financial information, leading to a severe lack of transparency. This, combined with likely extremely low liquidity and wide bid-ask spreads, makes the stock highly volatile and difficult to trade, exposing investors to substantial price manipulation risks and challenges in exiting positions.
How does Intellipharmaceutics International Inc. manage its product pipeline and commercialization strategy?
Intellipharmaceutics International Inc. manages its product pipeline by focusing on the research and development of novel and generic controlled-release oral solid dosage drugs, leveraging its patented Hypermatrix technology. The pipeline includes key candidates such as OxyContin (oxycodone hydrochloride controlled-release) for pain and Regabatin XR (pregabalin extended-release) for neuropathic pain, which are advanced through preclinical and clinical stages. For commercialization, the company utilizes a multi-pronged approach. It directly offers a portfolio of existing generic extended-release products in the United States. Additionally, it has established a crucial license and commercialization agreement with Par Pharmaceutical Inc., which facilitates broader market access and distribution for its products, allowing Intellipharmaceutics to focus on its core R&D competencies while leveraging a partner's commercial infrastructure.
What are the key factors to evaluate for IPCIF?
Intellipharmaceutics International Inc. (IPCIF) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does IPCIF data refresh on this page?
IPCIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IPCIF's recent stock price performance?
Intellipharmaceutics International Inc. (IPCIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Patented Hypermatrix technology offering advanced controlled-release drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IPCIF overvalued or undervalued right now?
Valuing Intellipharmaceutics International Inc. (IPCIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The market capitalization of $4.96M is unusual and may indicate an extremely low value or an error in data representation, but it is taken directly from the source.
- The 'CEO title' was inferred as 'Chief Executive Officer' as only 'Isa Odidi MBA,' was provided under 'CEO/LEADERSHIP'.
- CEO track record and background details were expanded based on the company's history and the CEO's implied role, as specific dates or detailed career history were not provided.
- Liquidity assessment for OTC Other tier is based on general characteristics of that market tier and the provided market cap.
- The 'Unknown' disclosure status for OTC is directly from the source data.